SGLT2 Inhibitors Linked to Lower Epilepsy Risk - Top_Thought_Leaders - MDSpire

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

  • By

  • Kathryn Wighton

  • April 7, 2026

  • 3 min

Share

Top Thought Leaders in Urology

Brief introduction explaining scope and methodology.

Original Source(s)

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

  • by Kathryn Wighton

  • April 7, 2026

Related Content

Retinal Imaging AI May Flag Brain Health Risk

Authors said AI-driven retinal screening still lacks evidence that it improves patient outcomes.

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

NIH researchers identify avenue for enhanced GLP-1-induced weight loss

  • May 22, 2026